- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Charleston Today
By the People, for the People
Ingevity Corporation Receives 'Hold' Rating from Analysts
Analysts give mixed recommendations on the specialty chemicals company's stock
Published on Feb. 26, 2026
Got story updates? Submit your updates here. ›
Ingevity Corporation (NYSE:NGVT) has received an average rating of 'Hold' from the five analysts covering the stock, according to a report from Marketbeat.com. One analyst has rated the stock as a 'Sell', two have given it a 'Hold' recommendation, and two have rated it a 'Buy'. The average 12-month price target among the analysts is $67.50.
Why it matters
Ingevity's stock performance and analyst ratings are important indicators for investors to consider when evaluating the company's outlook and potential future growth. The mixed ratings suggest there is some uncertainty around the company's prospects, which could impact its stock price and investor sentiment.
The details
The analysts' ratings on Ingevity's stock are based on the company's financial performance, market position, and future growth prospects. Some analysts see potential upside in the stock, while others are more cautious due to factors like the company's debt levels and competitive pressures in its markets.
- Ingevity's stock price closed at $70.33 on Thursday, February 26, 2026, up 1.0% on the day.
- The stock has a 52-week range of $28.49 to $77.46.
The players
Ingevity Corporation
A specialty chemicals and performance materials company headquartered in North Charleston, South Carolina.
Wall Street Zen
An equities research firm that lowered its rating on Ingevity from 'Strong Buy' to 'Buy'.
Jefferies Financial Group
An investment banking firm that reiterated a 'Buy' rating on Ingevity's stock.
Weiss Ratings
A research firm that maintained a 'Sell' rating on Ingevity's stock.
Wells Fargo & Company
A financial services firm that increased its price target on Ingevity's stock from $60 to $65 and maintained an 'Equal Weight' rating.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
The takeaway
Ingevity's mixed analyst ratings suggest there is some uncertainty around the company's future performance, which could impact investor sentiment and the stock price. The company's debt levels, competitive landscape, and ability to execute on its growth strategies will be key factors to watch going forward.





